Utilisation of medical resources of patients with pain undergoing an outpatient opioid therapy;Inanspruchnahme von medizinischen leistungen bei schmerzpatienten unter opioid-therapie in der ambulanten versorgung

Gesundheitswesen

Volumn 69, Issue 6, 2007, Pages 353-358

  Bruggenjurgen B ^a,b   Burkowitz, J ^b   Willich, S N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Alpha Care Management und Forschung in Gesundheitssystemen GmbH   (Germany)

Author keywords

Costs; Opioids; Pain therapy

Indexed keywords

FENTANYL; MORPHINE; OPIATE; OXYCODONE;

ANALYZER; ARTICLE; CONSULTATION; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; OUTPATIENT; PAIN; PRESCRIPTION; RESOURCE ALLOCATION; STATISTICAL ANALYSIS;

ADULT; AGED; AMBULATORY CARE; ANALGESICS, OPIOID; DRUG UTILIZATION; FEMALE; GERMANY; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PAIN; PREVALENCE; UTILIZATION REVIEW;

EID: 34547725219     PISSN: 09413790     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981679     Document Type: Article

References (25)

1. Bellach B-M, Ellert U, Radoschewski M. Epidemiologie des Schmerzes - Ergebnisse des Bundes-Gesundheitssurveys 1998. Bundesgesundheitsblatt 2000; 43: 424-431
2. Kohlmann T. Muskuloskelettale Schmerzen in der Bevölkerung. Der Schmerz 2003; 17: 405-411
3. Zimmermann M. Chronische Schmerzen - Epidemiologie und Versorgung in Deutschland. Orthopäde 2004; 33: 508-514
4. Göbel H. Epidemiologie und Kosten chronischer Schmerzen. Schmerz 2001; 15: 92-98
5. Ehrlich GE. Low back pain. Bulletin of the World Health Organiszation 2003; 81: 671-676
6. Podichetty VK, Mazanec DJ, Biscup RS. Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention. Postgrad Med J 2003; 79: 627-633
7. Kalso E, Edwards JE, Moore RA, MacQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-380
8. Cowan DT, Wilson-Barnett DJ, Griffiths P, Vaughan DJA, Gondhia A, Allan LG. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of Long-Term Opioid Drug Consumption and Subsequent Abstinence in Chronic Noncancer Pain Patients Receiving Controlled-Release Morphine. Pain Medicine 2005; 6: 113-121
9. Pain in Europe. Cambridge, Mundipharma International. 2004
10. Woolf AD, Zeidler H, Haglund U, Carr AJ, Chaussade S, Cucinotta D et al. Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis 2004; 63: 342-347
11. Ihle P, Schubert I, Radbruch L, Sabatowski R, Elsner F, Ferber L von. Opioid prescriptions in a representative regional health insurance survey. European Journal of Public Health 2002; 12: 63
12. Lindena G, Diener HC, Hildebrandt J, Klinger R, Maier C, Schops P et al. Leitlinien zur Schmerztherapie. Schmerz 2002; 16: 194-204
13. Banzer D, Greitemann B, Güttler K, Hankemeier U, Hasenbring M, Haupts M et al. Leitlinien-Clearingbericht "Chronischer Rückenschmerz". Niebüll: Verlag Videel, 2003
14. Arzneimitteltherapie in Deutschland - Bedarf und Realität Kassenärztliche Bundesvereinigung, editor. Kontext, 60 2003, Köln.
15. Loughlin JE, Cole JA, Dodd SL, Schein JR, Thornhill JC, Walker AM. Comparison of Resource Utilization by Patients Treated with Transdermal Fentanyl and Long-Acting Oral Opioids for Nonmalignant Pain. Pain Medcin 2002; 3: 47-55
16. Malkin JD, Ackerman SJ, Schein JR, Thornhill JC, Staats PS. (218) outcomes associated with fentanyl transdermal system and oxycodone controlled-release in a California medicaid population. Pain Med 2001; 2: 246-247
17. Malkin JD, Ackerman SJ, Schein J, Lochlear J, Ashburn M. Cost and utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release in a California Medicaid population. J Managed Care Pharm 2002; 8: 132-140
18. Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of fentanyl transdermal system for the treatment of chronic moderate to severe pain. Journal of Pain and Symptom Management 2001; 21: 129-143
19. Bóger RH, Schmidt G. Analgetika. In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 2005. Berlin: Springer, 2006; 277-290
20. Sorge J, Zenz M. Analyse des Verschreibungsverhaltens niedergelassener Ärzte für BtM-Analgetika. Schmerz 1990; 4: 151-156
21. Bolten WW, Zeidler H, Frölich JC. Schmerzen des Bewegungssystems und deren Behandlung in Deutschland. MMW-Fortschr Med 2005; 147: 85-90
22. Dietlein G, Schröder-Bernhardi D. Use of the MediPlus© patient database in healthcare research. Int J Clin Pharmacol Ther 2002; 40: 130-133
23. IMS DPM http://www.imshealth.de/sixcms/detail.php/224.2007.4-2-2007
24. Lehmann K, Radbruch L, Gockel H-H, Neighbors DM, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. European Journal of Health Economics 2002; 3: 111-119
25. Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochlorid controlled-release among patients with chronic nonmalignant pain. J Managed Care Pharm 2003; 3: 231